Using notifications data to increase hepatitis C testing and treatment rates in Queensland
DOI:
https://doi.org/10.33321/cdi.2023.47.62Keywords:
Hepatitis C, HCV, RNA testing, notifications, direct-acting antivirals, treatmentAbstract
Australia’s goal of eliminating hepatitis C by 2030 requires increases in uptake of and access to testing and treatment. As hepatitis C is a notifiable condition, health departments have access to information about people exposed to the hepatitis C virus (HCV), including the details of notifying clinicians who ordered their diagnostic pathology tests. Hepatitis C RNA testing confirms active infection that requires treatment, whereas a positive antibody test result only indicates prior exposure to the virus.
We undertook a pilot project in Queensland to follow up hepatitis C notifications with clinicians, aiming to increase HCV-RNA testing and treatment uptake. For all individuals with a first-time hepatitis C notification in Queensland between 3 November 2020 and 28 May 2021, we sought information regarding hepatitis C RNA testing from laboratories, excluding those cases diagnosed in prisons.
Cases who did not have RNA testing identified as part of or after their initial diagnostic tests were followed up via their notifying clinician. Interviews with selected clinicians were undertaken to improve our understanding of the follow-up process.
There were 769 new hepatitis C notifications during our study period: 244 had no subsequent RNA test identified and were followed up for this study. Of these, 134 cases were lost to follow-up; 26 were already being effectively case managed; 22 reported previous treatment and no further risk; and 62 were eligible for HCV-RNA testing. Twenty-six cases subsequently started hepatitis C treatment. Thirty-four percent of notifications that required follow-up resulted from testing initially requested in hospital settings.
Following up hepatitis C notifications can result in increased treatment rates; however, the process was resource-intensive and often failed to result in further contact between clinicians and patients. Our findings also highlight the importance of supporting better continuity of care between hospitals and community settings.
Downloads
References
Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol. 2016;31(4):872–82. doi: https://doi.org/10.1111/jgh.13223.
World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: WHO; June 2016. [Accessed on 5 August 2017.] Available from: https://apps.who.int/iris/handle/10665/246177.
Australian Government Department of Health and Aged Care. Fifth National Hepatitis C Strategy, 2018-2022. Canberra: Australian Government Department of Health and Aged Care; 2018. Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/fifth-national-hepatitis-c-strategy-2018-2022.pdf.
Dore GJ, Hajarizadeh B. Elimination of hepatitis C virus in Australia: laying the foundation. Infect Dis Clin North Am. 2018;32(2):269–79. doi: https://doi.org/10.1016/j.idc.2018.02.006.
The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia: Issue 12, July 2022. Sydney: University of New South Wales, the Kirby Institute; 2022. Available from: https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-12-july-2022.
Grebely J, Markus C, Causer LM, Silk D, Comben S, Lloyd AR et al. A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia. Lancet Gastroenterol Hepatol. 2023;8(3):204–7. doi: https://doi.org/10.1016/S2468-1253(22)00355-7.
Queensland State Government, Office of the Queensland Parliamentary Counsel. Public Health Act 2005. [Legislation.] Brisbane: Queensland Health; 2005. Available from: https://www.legislation.qld.gov.au/view/html/inforce/current/act-2005-048.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi: https://doi.org/10.1191/1478088706qp063oa.
Muller K, Hasan M. Treating chronic hepatitis C in general practice. Aust J Gen Pract. 2021;50(10):697–701. doi: https://doi.org/10.31128/AJGP-06-21-6029.
WHO Collaborating Centre for Viral Hepatitis. CHECCS pilot program: evaluation report November 2022. Melbourne: the Peter Doherty Institute for Infection and Immunity; November 2022. Available from: https://www.doherty.edu.au/uploads/content_doc/CHECCS_Evaluation_Report_Final_webNov2022.pdf
Selvey C, Fitzgerald TL, Sisnowski J, Sheppeard V. Use of routine notifications data to support DAA treatment uptake in New South Wales. [Conference presentation.] Prepared for the 12th Australasian Viral Hepatitis Conference, 16–18 August 2020. Sydney: New South Wales Government, NSW Health, Health Protection NSW; 2020. Available from: https://az659834.vo.msecnd.net/eventsairaueprod/production-ashm-public/fb06cd01413f4011afaf6c652e40af54.
Marukutira T, Moore K, Hellard M, Richmond J, Turner K, Pedrana A et al. Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial. J Hepatol. July 2022 2022;77(1):S541–2. doi: :https://doi.org/10.1016/S0168-8278(22)01406-4.
Wimsett J, Harper A, Jones P. Review article: Components of a good quality discharge summary: a systematic review. Emerg Med Australas. 2014;26(5):430–8. doi: https://doi.org/10.1111/1742-6723.12285.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
